AU2013216595B2 — 1' -substituted carba-nucleoside analogs for antiviral treatment
Assigned to Gilead Sciences Inc · Expires 2016-07-28 · 10y expired
What this patent protects
Ra8 x z R7 N 0-CH2 N Formula I Provided are pyrrolo[l,2-fj[1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2 f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates 5 and prodrugs thereof, wherein the I ' position of the nucleo…
USPTO Abstract
Ra8 x z R7 N 0-CH2 N Formula I Provided are pyrrolo[l,2-fj[1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2 f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates 5 and prodrugs thereof, wherein the I ' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. Formula (I), each XI or X2 is independently C-Ri" or N.
Drugs covered by this patent
- Veklury (remdesivir) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.